CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Earnings & Estimates
USA - NASDAQ:CMMB - US16385C2035 - ADR
2.5 USD
-0.1 (-3.85%)
2.58 USD
+0.08 (+3.2%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A 600.14% | N/A 245.59% | N/A 71.79% | ||||||
| EBITDA YoY % growth | -19.27M | -10.94M 43.23% | -12.34M -12.80% | -28.47M -130.71% | -25.392M 10.81% | -14.686M 42.16% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -19.55M | -10.96M 43.94% | -12.37M -12.86% | -28.53M -130.64% | -25.459M 10.76% | -14.739M 42.11% | N/A 17.44% | N/A -87.15% | N/A -10.97% | N/A -10.25% | N/A 12.37% | N/A 370.77% | N/A 217.06% | N/A 87.22% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -63.20 | N/A | -1.18 | -1.75 -47.88% | N/A 92.99% | -2.76 -2,154.90% | N/A 98.52% | N/A | N/A -400.00% | N/A 20.00% | N/A -25.00% | N/A 180.00% | N/A 1,050.00% | N/A 58.70% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.01 98.73% | -0.01 98.41% | -0.01 98.18% | -0.01 | -0.01 | -0.01 |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.814M -2.80% | -3.851M -19.84% | -6.298M -80.61% | -6.41M -183.39% | -6.634M -73.95% | -6.746M -75.19% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.56 -100.00% | -0.04 | -0.52 | -1,272.55% |
| Q4 2024 Q2Q % growth | -0.64 -3,037.25% | -0.32 | -0.32 | -101.11% |
| Q3 2024 Q2Q % growth | -0.80 -4,605.88% | -0.02 | -0.78 | -3,167.97% |
| Q2 2024 Q2Q % growth | -1.04 -3,298.69% | -0.06 | -0.98 | -1,720.73% |
| Q1 2024 Q2Q % growth | -0.28 65.00% | -0.02 | -0.26 | -1,272.55% |
| Q4 2023 Q2Q % growth | 97.21% | -0.02 | % | |
| Q3 2023 Q2Q % growth | -0.02 51.43% | -0.02 | 0.00 | 16.67% |
| Q2 2023 Q2Q % growth | 94.33% | -0.03 | % | |
| Q1 2023 Q2Q % growth | -0.80 -81.82% | -0.03 | -0.77 | -2,514.38% |
| Q4 2022 Q2Q % growth | -0.73 -65.91% | -0.04 | -0.69 | -1,689.22% |
| Q3 2022 Q2Q % growth | -0.04 86.54% | -0.34 | 0.30 | 89.60% |
| Q2 2022 Q2Q % growth | -0.54 -107.69% | -0.26 | -0.28 | -107.61% |
| Q1 2022 Q2Q % growth | -0.44 -100.00% | -0.25 | -0.19 | -76.07% |
| Q4 2021 Q2Q % growth | -0.44 | -0.11 | -0.33 | -317.47% |
| Q3 2021 Q2Q % growth | -0.26 | -0.15 | -0.11 | -75.79% |
| Q2 2021 Q2Q % growth | -0.26 | -0.12 | -0.14 | -121.65% |
| Q1 2021 Q2Q % growth | -0.22 97.25% | -0.44 | 0.22 | 49.84% |
| Q1 2020 Q2Q % growth | -8.00 85.71% | -1.88 | -6.12 | -326.26% |
| Q4 2019 Q2Q % growth | 31.20 | -2.04 | 33.24 | 1,629.41% |
| Q3 2019 Q2Q % growth | -34.40 | -2.99 | -31.41 | -1,049.75% |
| Q2 2019 Q2Q % growth | -4.00 | -2.69 | -1.31 | -48.54% |
| Q1 2019 Q2Q % growth | -56.00 | -2.61 | -53.39 | -2,044.61% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 89.61% |
| Revenue | N/A | N/A | N/A | N/A |